Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild Cognitive Impairment or Mild Dementia HALLE (SAALE), Germany and San Diego, […]
HALLE (SAALE), Germany, 12 March 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 5 February 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 18 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 04 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
HALLE (SAALE), Germany, 29 November 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]
Probiodrug AG to Publish its Third Quarter 2018 Business Update on November 29, 2018 HALLE (SAALE), Germany, 22 November 2018 – Probiodrug AG (Euronext […]
HALLE (SAALE), Germany, 29 October, 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]
SAPHIR trial data published in Alzheimer’s Research & Therapy HALLE (SAALE), Germany, 16 October 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company […]